Cargando…
Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
The spectrum of TKI-related adverse events (AEs) is variable. Pleural effusion (PE) is a frequent AE attributable to dasatinib treatment, while it is only rarely associated with nilotinib. The pathogenetic mechanism leading to PE during nilotinib therapy is still unknown and its management has not y...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513037/ https://www.ncbi.nlm.nih.gov/pubmed/36176390 http://dx.doi.org/10.3389/fonc.2022.1012268 |
_version_ | 1784797965637910528 |
---|---|
author | Pasquale, Raffaella Bucelli, Cristina Bellani, Valentina Zappa, Manuela Iurlo, Alessandra Cattaneo, Daniele |
author_facet | Pasquale, Raffaella Bucelli, Cristina Bellani, Valentina Zappa, Manuela Iurlo, Alessandra Cattaneo, Daniele |
author_sort | Pasquale, Raffaella |
collection | PubMed |
description | The spectrum of TKI-related adverse events (AEs) is variable. Pleural effusion (PE) is a frequent AE attributable to dasatinib treatment, while it is only rarely associated with nilotinib. The pathogenetic mechanism leading to PE during nilotinib therapy is still unknown and its management has not yet been defined. To the best of our knowledge, only a limited number of similar case reports have already been reported in the literature so far. Here, we describe the case of a 41-year-old CML patient who developed PE during first-line nilotinib, successfully treated with steroids and nilotinib permanent discontinuation. We highlight the differences among our patient and the others, proposing therapeutic strategies to solve this rare but still possible AE, of which physicians should be aware. |
format | Online Article Text |
id | pubmed-9513037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95130372022-09-28 Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event Pasquale, Raffaella Bucelli, Cristina Bellani, Valentina Zappa, Manuela Iurlo, Alessandra Cattaneo, Daniele Front Oncol Oncology The spectrum of TKI-related adverse events (AEs) is variable. Pleural effusion (PE) is a frequent AE attributable to dasatinib treatment, while it is only rarely associated with nilotinib. The pathogenetic mechanism leading to PE during nilotinib therapy is still unknown and its management has not yet been defined. To the best of our knowledge, only a limited number of similar case reports have already been reported in the literature so far. Here, we describe the case of a 41-year-old CML patient who developed PE during first-line nilotinib, successfully treated with steroids and nilotinib permanent discontinuation. We highlight the differences among our patient and the others, proposing therapeutic strategies to solve this rare but still possible AE, of which physicians should be aware. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9513037/ /pubmed/36176390 http://dx.doi.org/10.3389/fonc.2022.1012268 Text en Copyright © 2022 Pasquale, Bucelli, Bellani, Zappa, Iurlo and Cattaneo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Pasquale, Raffaella Bucelli, Cristina Bellani, Valentina Zappa, Manuela Iurlo, Alessandra Cattaneo, Daniele Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event |
title | Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event |
title_full | Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event |
title_fullStr | Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event |
title_full_unstemmed | Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event |
title_short | Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event |
title_sort | case report: pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: not only a dasatinib-related adverse event |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513037/ https://www.ncbi.nlm.nih.gov/pubmed/36176390 http://dx.doi.org/10.3389/fonc.2022.1012268 |
work_keys_str_mv | AT pasqualeraffaella casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent AT bucellicristina casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent AT bellanivalentina casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent AT zappamanuela casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent AT iurloalessandra casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent AT cattaneodaniele casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent |